We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

40 hedge funds and large institutions have $202M invested in Calidi Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

48% more funds holding

Funds holding: 27 → 40 (+13)

23% more capital invested

Capital invested by funds: $165M → $202M (+$37.7M)

0.13% more ownership

Funds ownership: 0.61% → 0.74% (+0.13%)

Holders
40
Holders Change
+13
Holders Change %
+48.15%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
9
Reduced
4
Closed
–
Calls
$599K
Puts
–
Net Calls
+$599K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$9.85M
2
SCM
Shaolin Capital Management
Florida
+$9.8M
3
AC
Aristeia Capital
Connecticut
+$9.75M
4
Millennium Management
Millennium Management
New York
+$4.87M
5
Nomura Holdings
Nomura Holdings
Japan
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$10.1M
2
AMH
Apollo Management Holdings
New York
-$438K
3
UBS Group
UBS Group
Switzerland
-$57.9K
4
AA
AQR Arbitrage
Connecticut
-$14.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
1
Polar Asset Management Partners
Ontario, Canada
$19.6M – – –
WP
2
Woodline Partners
California
$19.6M – – –
AMH
3
Apollo Management Holdings
New York
$19.1M -$438K -371 -2%
DCM
4
Driehaus Capital Management
Illinois
$14.8M – – –
6CM
5
683 Capital Management
New York
$11.9M +$9.85M +8,333 +500%
SCM
6
Shaolin Capital Management
Florida
$11.6M +$9.8M +8,298 +569%
BCM
7
Beryl Capital Management
California
$11.5M – – –
Marshall Wace
8
Marshall Wace
United Kingdom
$10.5M – – –
GL
9
Governors Lane
New York
$9.89M – – –
AC
10
Aristeia Capital
Connecticut
$9.79M +$9.75M +8,250 New
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$8.11M +$39K +33 +0.5%
PC
12
Periscope Capital
Ontario, Canada
$7.19M +$504K +427 +8%
SCM
13
Saba Capital Management
New York
$6.15M – – –
HCM
14
Highbridge Capital Management
New York
$5.53M -$10.1M -8,536 -65%
SC
15
Sculptor Capital
New York
$4.95M – – –
Millennium Management
16
Millennium Management
New York
$4.89M +$4.87M +4,123 New
RCM
17
Radcliffe Capital Management
Pennsylvania
$3.96M +$4.73K +4 +0.1%
WAM
18
Wolverine Asset Management
Illinois
$3.23M +$1.37M +1,163 +75%
OCM
19
Oaktree Capital Management
California
$2.97M – – –
WRBC
20
W.R. Berkley Corp
Connecticut
$2.33M – – –
Nomura Holdings
21
Nomura Holdings
Japan
$1.83M +$1.83M +1,547 New
RL
22
RPO LLC
Connecticut
$1.72M +$1.72M +1,453 New
CC
23
Centiva Capital
New York
$1.72M +$1.71M +1,450 New
Blackstone Inc
24
Blackstone Inc
New York
$1.69M +$1.68M +1,424 New
Goldman Sachs
25
Goldman Sachs
New York
$1.26M +$365K +309 +41%
1
2

CLDI Hedge Fund Activity: Q1 2022 in Review

40 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2022, worth a combined $202M — up 23% from $165M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CLDI positions and 0 closed out — a net gain of 13 holders — while 9 added to existing stakes and 4 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $9.85M. The largest seller was Highbridge Capital Management, cutting an estimated $10.1M.

  • 40 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2022, up from 27 in Q4 2021.
  • Funds reported $202M of Calidi Biotherapeutics stock for Q1 2022, up 23% quarter-over-quarter.
  • 13 funds opened new Calidi Biotherapeutics positions in Q1 2022 and 0 closed out, a net change of +13 holders.
  • The largest Calidi Biotherapeutics buyer in Q1 2022 was 683 Capital Management, an estimated $9.85M added.
  • The largest Calidi Biotherapeutics seller in Q1 2022 was Highbridge Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2022.